Bugworks Research: India’s Drug-Discovery Startup Developing a New Antibiotic Class Against Superbugs

For decades, antibiotics transformed infections that once killed millions into treatable diseases. That advantage is now under increasing pressure as bacteria evolve resistance to drugs that hospitals have relied upon for years.

The problem is particularly serious with multidrug-resistant bacteria, which can survive several classes of antibiotics and cause difficult-to-treat pneumonia, bloodstream infections, urinary infections and other life-threatening diseases.

From its research base in Bengaluru, Bugworks Research is attempting something considerably harder than producing another version of an existing antibiotic. The company is developing an entirely new class of broad-spectrum antibacterial compounds designed to attack drug-resistant bacteria through a different mechanism.

Its lead candidate, BWC0977, has already entered human clinical development and is being co-developed with the Global Antibiotic Research and Development Partnership (GARDP). Bugworks is simultaneously applying its drug-discovery capabilities to a second major challenge: developing new small-molecule medicines against difficult cancers.

An Indian Drug-Discovery Company Born in Bengaluru

Bugworks was established in 2014 and incubated at the Centre for Cellular and Molecular Platforms, or C-CAMP, in Bengaluru. Its research organisation grew from a team with extensive experience in antibacterial drug discovery, including scientists who had previously worked on infectious-disease programmes at AstraZeneca in India.

The company today has a global corporate structure, with its headquarters in the United States and subsidiaries in India and Australia. However, its principal research and development operations have deep roots in Bengaluru.

That distinction is important.

Bugworks represents a relatively rare segment of India’s biotechnology ecosystem. It is not merely manufacturing established medicines after their patents expire. Its scientists are attempting original drug discovery, beginning with molecular design and medicinal chemistry and progressing through preclinical studies and human clinical trials.

Developing a completely new antibiotic can take many years, cost hundreds of millions of dollars and fail at numerous stages. That makes Bugworks’ progress particularly significant for India’s ambitions in pharmaceutical innovation.

The Superbug Problem

Antimicrobial resistance, or AMR, develops when microorganisms evolve mechanisms that allow them to survive medicines that previously killed them.

Antibiotic use creates evolutionary pressure. Susceptible bacteria die, while organisms carrying resistance mechanisms can survive and multiply. Over time, bacteria can become resistant to multiple drug classes.

The consequences are especially dangerous in hospitals.

Pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa can cause severe infections in critically ill patients. Some strains have acquired resistance to carbapenems and other antibiotics normally reserved for serious infections.

This creates a worrying medical situation in which doctors may identify the bacteria responsible for an infection but have increasingly few drugs capable of treating it.

The World Health Organization consequently maintains a list of bacterial pathogens for which new antibiotics are urgently needed. Bugworks designed its antibacterial programme around many of these high-priority organisms.

BWC0977: Bugworks’ Lead Antibiotic Candidate

The most advanced product emerging from Bugworks’ research is BWC0977.

It belongs to a class known as Novel Bacterial Topoisomerase Inhibitors, or NBTIs.

Bacteria must repeatedly copy their DNA in order to reproduce. During this process, enzymes called DNA gyrase and topoisomerase IV manage the twisting, separation and organisation of bacterial DNA.

BWC0977 is designed to inhibit both enzymes.

By disrupting these two critical components of bacterial DNA replication, the compound can prevent susceptible bacteria from multiplying and surviving.

Importantly, although existing fluoroquinolone antibiotics also interact with bacterial topoisomerases, BWC0977 belongs to a chemically and mechanistically differentiated group of inhibitors. Bugworks has therefore attempted to create a drug capable of remaining active against bacteria that have already acquired resistance to several established antibiotics.

Attacking Two Essential Bacterial Targets

The dual-target approach is one of the most interesting features of Bugworks’ technology.

Instead of relying on a single bacterial vulnerability, BWC0977 inhibits both DNA gyrase and topoisomerase IV. Bugworks and its development partners believe this design could make resistance more difficult to develop than it would be against a compound dependent on only one target.

Its molecular design also attempts to overcome another common bacterial defence.

Gram-negative bacteria possess sophisticated cell envelopes and can use efflux pumps to eject harmful compounds before those compounds accumulate to lethal concentrations inside the cell.

Bugworks’ programme was specifically engineered to improve penetration and reduce susceptibility to these bacterial efflux mechanisms.

Solving these problems simultaneously — bacterial entry, efflux avoidance, potency and human safety — is one reason developing new antibiotics against Gram-negative pathogens is exceptionally difficult.

Broad-Spectrum Activity Against Resistant Bacteria

Laboratory studies published in Nature Communications in 2024 demonstrated BWC0977’s activity against a broad collection of multidrug-resistant organisms.

Researchers reported activity against Gram-negative bacteria, Gram-positive bacteria, anaerobic organisms and several biothreat pathogens. The compound also retained activity against isolates resistant to important antibiotic classes including fluoroquinolones, carbapenems and colistin.

Among the organisms relevant to its development programme are resistant strains of:

Klebsiella pneumoniae,
Acinetobacter baumannii,
Pseudomonas aeruginosa,
Escherichia coli,
Staphylococcus aureus and
Enterococcus faecium.

Bugworks’ current pipeline also lists activity against WHO critical- and high-priority pathogens as a central objective of its GYROX antibacterial platform.

This breadth could become particularly valuable because doctors treating critically ill patients frequently have to begin therapy before laboratories have completely identified the pathogen responsible for an infection.

A genuinely broad-spectrum new antibiotic could therefore provide doctors with an additional option while diagnostic information is still being obtained.

Designed for Both Intravenous and Oral Treatment

Bugworks is also developing BWC0977 with another feature that could significantly influence how the medicine is eventually used.

The programme includes both intravenous and oral formulations.

Patients with severe infections generally begin treatment in hospitals using intravenous antibiotics. Once their condition improves, doctors often prefer to switch them to oral medicines so that treatment can continue without prolonged hospitalisation.

However, suitable oral options against resistant Gram-negative infections remain limited.

Bugworks therefore describes BWC0977 as an IV-to-oral step-down antibiotic. If clinical development succeeds, the same antibacterial platform could potentially support intensive hospital treatment followed by oral therapy outside the hospital.

That could reduce hospital stays, treatment costs and dependence on intravenous therapy.

Human Trials Have Already Begun

BWC0977 has moved beyond laboratory and animal testing into human clinical development.

A first-in-human Phase 1 programme evaluated intravenous single ascending doses in healthy volunteers. Results reported in Nature Communications found that the tested doses were well tolerated and produced dose-proportional exposure consistent with expectations generated from preclinical studies.

These results do not establish that BWC0977 is an effective treatment for infected patients. Phase 1 studies primarily assess characteristics such as safety, tolerability and how the human body processes a candidate drug.

The programme therefore still faces substantial clinical development before the medicine could potentially receive regulatory approval.

GARDP’s 2026 material continues to describe BWC0977 as being in Phase 1 clinical development.

Nevertheless, reaching human trials represents an important milestone for an antibiotic discovered through a research programme with major development activities in India.

A $20 Million Global Partnership

Bugworks’ antibiotic programme has attracted support from some of the world’s most important organisations working on antimicrobial resistance.

In 2017, the US-based CARB-X accelerator selected Bugworks’ programme for funding. CARB-X reports an initial investment of up to $2.6 million, with potential additional option payments taking support to as much as $3.6 million.

The programme later attracted support from GARDP, a not-for-profit organisation created to accelerate antibiotics capable of addressing major global health needs.

Bugworks and GARDP entered a collaboration and licence agreement to jointly develop BWC0977. GARDP committed up to $20 million to support further development, including work intended to advance the compound through later clinical stages and eventually toward commercialisation if trials are successful.

The scale of that partnership reflects the international interest surrounding a potential new broad-spectrum antibiotic.

Access Is Being Considered Before the Drug Is Approved

One unusual aspect of the Bugworks-GARDP partnership is that access planning is happening while the medicine is still being developed.

New antibiotics present a difficult economic problem.

Society urgently needs them, but doctors must use successful new antibiotics carefully so that resistance does not emerge rapidly. That means pharmaceutical companies cannot necessarily generate revenue by selling them in the enormous volumes associated with medicines for chronic diseases.

At the same time, new antibiotics must remain affordable enough for hospitals in countries where resistant infections are widespread.

GARDP says its collaboration with Bugworks aims to make BWC0977 accessible in up to 146 countries if development and regulatory approval are ultimately successful.

This links drug discovery with another challenge particularly relevant to India and the wider Global South: ensuring that breakthrough medicines reach patients rather than remaining available only in wealthy healthcare systems.

Indian Government Support Was Part of the Development Journey

BWC0977’s scientific development has also received support from India’s biotechnology ecosystem.

The peer-reviewed research describing the compound acknowledges funding from the Biotechnology Industry Research Assistance Council, or BIRAC, under the Department of Biotechnology’s Biotechnology Industry Partnership Programme.

This is important from a Make in India perspective because advanced pharmaceutical innovation rarely emerges from a company working entirely in isolation.

Successful drug discovery requires long-term interaction among universities, biotechnology incubators, government programmes, investors, clinical organisations, contract research companies and international development partners.

Bugworks’ journey from C-CAMP incubation in Bengaluru to an antibiotic candidate undergoing human trials provides a strong example of how such an ecosystem can develop.

The GYROX Platform Goes Beyond One Drug

BWC0977 is not intended to be the end of Bugworks’ antibacterial programme.

The company calls its broader discovery platform GYROX and lists a next-generation programme known as GYROX NXTGEN in its pipeline.

The objective remains the development of broad-spectrum small-molecule antibiotics that can work against critical-care as well as community infections while supporting both intravenous and oral treatment.

Creating a repeatable drug-discovery platform could ultimately be more valuable than producing a single successful medicine.

Bugworks choregraphed the chemistry and biological understanding developed during BWC0977 to additional compounds, India could gain an indigenous knowledge base in one of the most difficult fields of modern pharmaceutical research.

Bugworks Is Also Building an Oncology Pipeline

Antibiotics are only one side of Bugworks’ research.

The company is simultaneously developing small-molecule cancer therapeutics, particularly for difficult solid tumours characterised by low oxygen levels and strongly immunosuppressive tumour environments.

One area of interest is the adenosine pathway.

Tumours can accumulate adenosine in their surrounding microenvironment. This molecule can suppress immune-cell activity, effectively helping the tumour create a biological environment in which the immune system becomes less capable of attacking cancer cells.

Bugworks is developing small molecules intended to interfere with this process.

Its lead oncology candidate, BWC2094, targets A2A and A2B adenosine receptors as well as ENT1. Bugworks lists potential applications across several immunologically suppressed solid tumours, including colorectal, lung, triple-negative breast, pancreatic, prostate, renal, head-and-neck and ovarian cancers.

The company says its lead anticancer programme has reached the stage of preparation for an Investigational New Drug submission, although it remains substantially earlier in development than an approved cancer medicine.

Moving India Beyond Generic Pharmaceuticals

India has built one of the world’s strongest pharmaceutical manufacturing industries.

Indian companies produce huge quantities of generic drugs, vaccines and active pharmaceutical ingredients and supply medicines to markets across the world.

The next technological step is considerably harder: discovering completely new medicines.

Novel drug development requires capabilities in medicinal chemistry, computational design, microbiology, pharmacology, toxicology, formulation, clinical development and intellectual property. Unlike generic medicines, scientists cannot begin with a proven molecule and recreate it. They must identify and optimise the molecule themselves while accepting a high possibility of failure.

Bugworks operates in precisely this high-risk area.

Its Bengaluru research teams have helped take BWC0977 from molecular discovery through preclinical testing and into human clinical development. The project has subsequently attracted international partnerships because its potential value extends far beyond the Indian market.

India’s AMR Challenge Makes the Technology Particularly Relevant

Antimicrobial resistance is a global problem, but its consequences can be particularly serious in countries with large populations, high infectious-disease burdens and extensive antibiotic consumption.

India therefore has a direct strategic interest in building its own capabilities for next-generation antibiotic research.

The solution will not come from new medicines alone. Better infection prevention, hospital hygiene, vaccination, diagnostic testing and more responsible antibiotic use remain essential.

However, stewardship cannot completely replace drug discovery.

Even with careful use, bacteria continue evolving. Healthcare systems therefore need a pipeline capable of periodically producing genuinely new antibacterial mechanisms.

Bugworks is attempting to build part of that pipeline from India.

From Bengaluru Laboratory to a Potential Global Medicine

BWC0977 still has a long journey ahead.

It must successfully complete further clinical studies demonstrating appropriate dosing, safety and efficacy in patients. Large trials will be needed before regulators can determine whether its benefits outweigh its risks. Manufacturing and commercialisation must then be established at appropriate scale.

Most experimental medicines never complete this entire journey.

Bugworks therefore cannot yet claim to have delivered a new antibiotic to hospitals. BWC0977 remains an investigational drug.

What the company has already demonstrated, however, is significant.

A research team operating from India’s biotechnology ecosystem has designed a new antibacterial molecule, demonstrated activity against formidable multidrug-resistant pathogens, taken it into first-in-human studies, published the scientific results and attracted backing from organisations such as BIRAC, CARB-X and GARDP.

That represents the deeper ambition behind Make in India in pharmaceuticals.

The objective is not simply to manufacture more medicines inside the country. It is to develop the scientific capability to invent medicines that do not yet exist.

---